Latest Breaking News On - Bellvitge institute for biomedical research - Page 1 : comparemela.com

Dr Piulats on the Rationale For Evaluating Predictive Biomarkers for Talazoparib/Enzalutamide in mCRPC

Dr Piulats on the Rationale For Evaluating Predictive Biomarkers for Talazoparib/Enzalutamide in mCRPC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Institut catalJosep maria piulats rodriguezBellvitge institute for biomedical researchSpanish melanoma groupUveal melanomaBellvitge instituteBiomedical research

Lack of cellular prion protein might cause symptoms of epilepsy and learning deficits

The cellular prion protein (PrPC), a protein in the surface of the neuronal cells, is imbalanced in human patients with neurodegenerative diseases such as

Comunidad autonoma de catalunaCaixa banking foundationInstitute of complex systemsSpanish ministry of scienceInstitute for bioengineering of cataloniaUniversity pablo de olavideCentre for biomedical research on neurodegenerative diseasesDepartment of innovationBellvitge institute for biomedical researchInstitute of neurosciences ubneuroUniversity hospital of zurich switzerlandHealth sciencesCommittee of universitiesProfessor josBarcelona science parkBiomedical research

Big data analysis finds cancer s key vulnerabilities

E-Mail NEW YORK, NY (Jan. 11, 2021) Thousands of different genetic mutations have been implicated in cancer, but a new analysis of almost 10,000 patients found that regardless of the cancer s origin, tumors could be stratified in only 112 subtypes and that, within each subtype, the Master Regulator proteins that control the cancer s transcriptional state were virtually identical, independent of the specific genetic mutations of each patient. The study, published Jan. 11 in Cell, confirms that Master Regulators provide the molecular logic that integrates the effect of many different and patient-specific mutations to implement the transcriptional state of a specific tumor subtype, thus greatly expanding the fraction of patients who may respond to the same treatment.

New yorkUnited statesMailman school of public healthColumbia universityLhospitalet de llobregatComunidad autonoma de catalunaAsuntos economicosy transformacionPrems subramaniamMarianoj alvarez darwinhealthMariano alverezEugenef douglassAndrea califanoSalud carlosMarianoj alvarezColumbia university irving medical centerVagelos college of physicians

Could Amgen s Xgeva boost immunotherapy in breast cancer?

Dec 14, 2020 9:10am Improving the efficacy of immuno-oncology drugs in breast cancer was the focus of a new study led by researchers in Spain. (National Cancer Institute) Amgen’s osteoporosis drug denosumab is approved as Xgeva for the prevention and treatment of some bone metastases in cancer. But could the drug’s mechanism of action help breast cancer patients respond to immunotherapy drugs that typically don’t work well in those tumors? That was the premise behind a new study led by the Bellvitge Institute for Biomedical Research (IDIBELL) in Spain and partially funded by Amgen. The researchers studied cells from mouse models and from premenopausal patients with luminal breast cancer to determine whether Xgeva’s inhibition of a signaling pathway called RANK might make the tumor cells more sensitive to immunotherapy.

Eva gonzalez suarezNature communicationsUniversity of cincinnatiBellvitge institute for biomedical researchSpanish national cancer research centerBellvitge instituteBiomedical researchUnified clinical data captureஈவா கோன்சலஸ் ஸ்யூவாரெஸ்இயற்கை தகவல்தொடர்புகள்பல்கலைக்கழகம் ஆஃப் ஸிந்ஸந்யாடீஸ்பானிஷ் தேசிய புற்றுநோய் ஆராய்ச்சி மையம்உயிர் மருத்துவ ஆராய்ச்சிஒருங்கிணைந்த மருத்துவ தகவல்கள் பிடிப்பு

Osteoporosis drug also promotes infiltration of immune cells in breast tumors

Osteoporosis drug also promotes infiltration of immune cells in breast tumors The team of Eva González-Suarez, from the CNIO and IDIBELL, and the team of Christos Sotiriou, from the Jules Bordet Institute, demonstrate that a drug already used to treat osteoporosis promotes the infiltration of immune cells in breast tumors These findings propose a new target to increase the antitumor immune response and make breast cancer more sensitive to immunotherapy Despite the success of immunotherapy in the treatment of cancers such as lung or melanoma, it is still not effective in breast cancers for being cold , with low infiltration of immune cells.

Investigaciones oncologicasEva gonzEva gonzalez suarezEmily hendersonNature communicationsBellvitge institute for biomedical researchSpanish national cancer research centerMetastasis groupJules bordet instituteChristos sotiriouBellvitge instituteBiomedical researchCentro nacional de investigacionesஈவா கோன்ஸ்ஈவா கோன்சலஸ் ஸ்யூவாரெஸ்எமிலி ஹென்டர்சன்